These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27687641)

  • 41. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.
    O'Brien S
    Br J Clin Pharmacol; 2015 Feb; 79(2):168-72. PubMed ID: 25601037
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D
    Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
    [No Abstract]   [Full Text] [Related]  

  • 44. Traditional drug-discovery model ripe for reform.
    Cressey D
    Nature; 2011 Mar; 471(7336):17-8. PubMed ID: 21368796
    [No Abstract]   [Full Text] [Related]  

  • 45. Model-based drug development: a rational approach to efficiently accelerate drug development.
    Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
    Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Translational regenerative medicine research: essential to discovery and outcome.
    Mason C; Dunnill P
    Regen Med; 2007 May; 2(3):227-9. PubMed ID: 17511558
    [No Abstract]   [Full Text] [Related]  

  • 48. Challenges of antibacterial discovery revisited.
    Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ
    Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Why is big Pharma getting out of antibacterial drug discovery?
    Projan SJ
    Curr Opin Microbiol; 2003 Oct; 6(5):427-30. PubMed ID: 14572532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of development of new antimicrobial drugs: a potential serious threat to public health.
    Norrby SR; Nord CE; Finch R;
    Lancet Infect Dis; 2005 Feb; 5(2):115-9. PubMed ID: 15680781
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
    Tanaka SK; Steenbergen J; Villano S
    Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overcoming the current deadlock in antibiotic research.
    Schäberle TF; Hack IM
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability.
    Bart SM; Farley JJ; Bala S; Amini T; Cox E
    Clin Infect Dis; 2021 Apr; 72(8):1422-1428. PubMed ID: 32161946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. To make better therapeutics, companies strive to increase the content of results and get them faster.
    Szpir M
    Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
    [No Abstract]   [Full Text] [Related]  

  • 56. Antibiotics Clinical Development and Pipeline.
    Hesterkamp T
    Curr Top Microbiol Immunol; 2016; 398():447-474. PubMed ID: 26162565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Future antibiotics scenarios: is the tide starting to turn?
    Theuretzbacher U
    Int J Antimicrob Agents; 2009 Jul; 34(1):15-20. PubMed ID: 19342202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibiotics at the crossroads.
    Nathan C
    Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
    [No Abstract]   [Full Text] [Related]  

  • 60. The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?
    Talbot GH; Jezek A; Murray BE; Jones RN; Ebright RH; Nau GJ; Rodvold KA; Newland JG; Boucher HW;
    Clin Infect Dis; 2019 Jun; 69(1):1-11. PubMed ID: 30715222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.